{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Established Pharmacologic Class [EPC]" in comments (approximate match)
Status:
US Approved Rx
(1976)
Source:
BLA017836
(1976)
Source URL:
First approved in 1976
Source:
BLA017836
Source URL:
Class:
PROTEIN
Iodide ion I-125 is radioisotope of iodine with half-life 59.4 days. It decays with the emission of low-energy gamma rays. It is used as a source for bone densitometry devices, protein iodination. Seeds implantations with I-125 are used in the clinics for the treatment of prostate cancer, malignant biliary obstruction, non-small cell lung cancer, colorectal cancer, uveal melanoma, and other tumors.
Status:
US Approved OTC
Source:
21 CFR 346.18(a) anorectal:astringent calamine
Source URL:
First marketed in 1921
Class:
PROTEIN
Targets:
Conditions:
There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.
Status:
US Previously Marketed
Source:
Bexxar
(2003)
Source URL:
First approved in 2003
Source:
Bexxar
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2013)
Source:
NDA205098
(2013)
Source URL:
First approved in 2010
Source:
NDA021201
Source URL:
Class:
POLYMER
Targets:
Conditions:
Polidocanol is a non-ionic surfactant sclerosing agent indicated to treat uncomplicated spider veins and uncomplicated reticular veins in the lower extremity. Polidocanol also is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system above and below the knee. When administered, polidocanol locally damages blood vessel endothelium. Following the endothelial damage, platelets aggregate at the site and attach to the venous wall eventually resulting in a dense network of platelets, cellular debris, and fibrin that occludes the vessel. Eventually the vessel is replaced by connective fibrous tissue. Adverse reactions include pain in extremity, infusion site thrombosis, contusion/injection site hematoma, limb discomfort and some others.
Status:
US Approved Rx
(2011)
Source:
ANDA090313
(2011)
Source URL:
First approved in 1955
Source:
NDA205489
Source URL:
Class:
POLYMER
Status:
US Approved OTC
Source:
21 CFR 346.18(a) anorectal:astringent calamine
Source URL:
First marketed in 1921
Source:
Solution of Ferric Subsulphate U.S.P.
Source URL:
Class:
POLYMER
Conditions:
Ferric Ammonium EDTA Solution is normally used as a photographic chemical for a bleaching agent in the process of colour washing. It is also used as a complexing, and oxidizing agent & as a fertilizer and catalyst. EDTA acid are colourless, water-soluble solid that are widely used to dissolve scale. The usefulness of these ammonium salts arise because of its role as a chelating agent, i.e. its ability to "sequester" metal ions such as Ca2+ and Fe3+.
Status:
US Approved Allergenic Extract
Source:
BLA103888
Source URL:
First approved in 1974
Source:
NDA022404
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Allergenic Extract
(1981)
Source:
BLA101833
(1981)
Source URL:
First approved in 1972
Source:
BLA102192
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Allergenic Extract
(1965)
Source:
BLA103753
(1965)
Source URL:
First approved in 1965
Source:
BLA103753
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Allergenic Extract
(1975)
Source:
BLA103753
(1975)
Source URL:
First approved in 1941
Source:
BLA103888
Source URL:
Class:
STRUCTURALLY DIVERSE